Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
Merck call volume above normal and directionally bullish » 12:25
04/16/21
04/16
12:25
04/16/21
12:25
MRK

Merck

$77.30 /

+0.63 (+0.82%)

Bullish option flow…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRK Merck
$77.30 /

+0.63 (+0.82%)

MRK Merck
$77.30 /

+0.63 (+0.82%)

08:59 Today William Blair
Atea selloff on Merck update unwarranted, says William Blair
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/08/21 Alliance Global Partners
Alliance Global Partners sees Fast Track for Immutep efti as meaningful positive
04/08/21 H.C. Wainwright
Alkermes collaboration not as big as investors wanted, says H.C. Wainwright
MRK Merck
$77.30 /

+0.63 (+0.82%)

MRK Merck
$77.30 /

+0.63 (+0.82%)

MRK Merck
$77.30 /

+0.63 (+0.82%)

MRK Merck
$77.30 /

+0.63 (+0.82%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:01
04/16/21
04/16
12:01
04/16/21
12:01
MS

Morgan Stanley

$78.53 /

-2.36 (-2.92%)

, BK

BNY Mellon

$46.19 /

-1.83 (-3.81%)

, CFG

Citizens Financial

$44.59 /

-0.08 (-0.18%)

, STT

State Street

$81.09 /

-5.44 (-6.29%)

, ALXN

Alexion

$163.98 /

+6.55 (+4.16%)

, AZN

AstraZeneca

$50.90 /

+0.06 (+0.12%)

, JNJ

Johnson & Johnson

$161.62 /

+1.12 (+0.70%)

, LSCC

Lattice Semiconductor

$56.81 /

+5.68 (+11.11%)

, PPG

PPG

$170.26 /

+16.4 (+10.66%)

, AA

Alcoa

$35.37 /

+2.51 (+7.64%)

, EDIT

Editas Medicine

$34.50 /

-6.41 (-15.67%)

, SPLK

Splunk

$135.90 /

-12.5 (-8.42%)

The major averages are…

ShowHide Related Items >><<
MS Morgan Stanley
$78.53 /

-2.36 (-2.92%)

BK BNY Mellon
$46.19 /

-1.83 (-3.81%)

CFG Citizens Financial
$44.59 /

-0.08 (-0.18%)

STT State Street
$81.09 /

-5.44 (-6.29%)

ALXN Alexion
$163.98 /

+6.55 (+4.16%)

AZN AstraZeneca
$50.90 /

+0.06 (+0.12%)

JNJ Johnson & Johnson
$161.62 /

+1.12 (+0.70%)

LSCC Lattice Semiconductor
$56.81 /

+5.68 (+11.11%)

PPG PPG
$170.26 /

+16.4 (+10.66%)

AA Alcoa
$35.37 /

+2.51 (+7.64%)

EDIT Editas Medicine
$34.50 /

-6.41 (-15.67%)

SPLK Splunk
$135.90 /

-12.5 (-8.42%)

MS Morgan Stanley
$78.53 /

-2.36 (-2.92%)

04/09/21 JMP Securities
Goldman Sachs price target raised to $400 from $338 at JMP Securities
04/07/21 Barclays
Morgan Stanley price target raised to $98 from $95 at Barclays
04/01/21 Deutsche Bank
Morgan Stanley price target raised to $79 from $68 at Deutsche Bank
04/01/21 UBS
Morgan Stanley price target raised to $92 from $84 at UBS
BK BNY Mellon
$46.19 /

-1.83 (-3.81%)

04/09/21 Deutsche Bank
BNY Mellon price target raised to $54 from $50 at Deutsche Bank
04/07/21 Barclays
BNY Mellon price target raised to $57 from $55 at Barclays
03/26/21 JPMorgan
JPMorgan sees BNY Mellon, Wells Fargo among banks with most buyback capacity
03/24/21
Fly Intel: Top five analyst upgrades
CFG Citizens Financial
$44.59 /

-0.08 (-0.18%)

04/09/21 Jefferies
Citizens Financial price target raised to $47 from $42 at Jefferies
04/07/21 Barclays
Citizens Financial price target raised to $54 from $49 at Barclays
04/01/21 Deutsche Bank
Citizens Financial price target raised to $50 from $44 at Deutsche Bank
03/30/21 Stephens
Citizens Financial price target raised to $54 from $45 at Stephens
STT State Street
$81.09 /

-5.44 (-6.29%)

04/09/21 Deutsche Bank
State Street price target raised to $100 from $97 at Deutsche Bank
04/07/21 Barclays
State Street price target raised to $104 from $99 at Barclays
04/01/21 Wells Fargo
State Street price target raised to $90 from $83 at Wells Fargo
04/01/21 Morgan Stanley
State Street price target raised to $103 from $102 at Morgan Stanley
ALXN Alexion
$163.98 /

+6.55 (+4.16%)

03/23/21
Fly Intel: Top five analyst downgrades
03/23/21 SVB Leerink
SVB Leerink moving to sidelines on Alexion, five others on industry concerns
03/23/21 SVB Leerink
Alexion downgraded to Market Perform from Outperform at SVB Leerink
02/04/21 Piper Sandler
Alexion downgraded to Neutral ahead of expected deal closing at Piper Sandler
AZN AstraZeneca
$50.90 /

+0.06 (+0.12%)

04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/12/21
Fly Intel: Top five analyst downgrades
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/12/21 Argus
AstraZeneca downgraded to Hold from Buy at Argus
JNJ Johnson & Johnson
$161.62 /

+1.12 (+0.70%)

04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/13/21 Goldman Sachs
J&J vaccine had numerical blood clot imbalance in trial, says Goldman Sachs
04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 JPMorgan
Vaccine pause 'incremental negative' for J&J, says JPMorgan
LSCC Lattice Semiconductor
$56.81 /

+5.68 (+11.11%)

02/17/21 Craig-Hallum
Lattice Semiconductor price target raised to $40 from $31 at Craig-Hallum
02/17/21 KeyBanc
Lattice Semiconductor price target raised to $57 from $50 at KeyBanc
02/17/21 Cowen
Lattice Semiconductor price target raised to $56 from $48 at Cowen
02/17/21 Susquehanna
Lattice Semiconductor price target raised to $56 from $52 at Susquehanna
PPG PPG
$170.26 /

+16.4 (+10.66%)

04/15/21 Citi
Citi opens '30-day negative catalyst watch' on Axalta, PPG
04/07/21 Wells Fargo
PPG price target raised to $173 from $165 at Wells Fargo
03/15/21 Credit Suisse
PPG assumed with a Neutral at Credit Suisse
01/26/21 BofA
PPG upgraded to Buy from Neutral at BofA
AA Alcoa
$35.37 /

+2.51 (+7.64%)

08:17 Today B. Riley
Alcoa price target raised to $36 from $20 at B. Riley
07:34 Today BMO Capital
Alcoa price target raised to $38 from $36 at BMO Capital
03/24/21
Fly Intel: Top five analyst upgrades
03/24/21 Morgan Stanley
Morgan Stanley upgrades Alcoa to Overweight on better prospects for aluminum
EDIT Editas Medicine
$34.50 /

-6.41 (-15.67%)

09:55 Today
Fly Intel: Top five analyst initiations
04:56 Today Goldman Sachs
Editas Medicine initiated with a Sell at Goldman Sachs
03/22/21 Credit Suisse
Editas Medicine initiated with an Outperform at Credit Suisse
03/17/21 Guggenheim
Editas Medicine assumed with a Neutral at Guggenheim
SPLK Splunk
$135.90 /

-12.5 (-8.42%)

09:54 Today
Fly Intel: Top five analyst downgrades
05:18 Today KeyBanc
Splunk downgraded to Sector Weight from Overweight at KeyBanc
04/08/21 BofA
Splunk reinstated with a Buy at BofA
04/08/21 BofA
Splunk reinstated with a Buy at BofA
MS Morgan Stanley
$78.53 /

-2.36 (-2.92%)

BK BNY Mellon
$46.19 /

-1.83 (-3.81%)

CFG Citizens Financial
$44.59 /

-0.08 (-0.18%)

STT State Street
$81.09 /

-5.44 (-6.29%)

ALXN Alexion
$163.98 /

+6.55 (+4.16%)

AZN AstraZeneca
$50.90 /

+0.06 (+0.12%)

JNJ Johnson & Johnson
$161.62 /

+1.12 (+0.70%)

LSCC Lattice Semiconductor
$56.81 /

+5.68 (+11.11%)

PPG PPG
$170.26 /

+16.4 (+10.66%)

AA Alcoa
$35.37 /

+2.51 (+7.64%)

EDIT Editas Medicine
$34.50 /

-6.41 (-15.67%)

SPLK Splunk
$135.90 /

-12.5 (-8.42%)

  • 21
    Jan
  • 24
    Jun
MS Morgan Stanley
$78.53 /

-2.36 (-2.92%)

BK BNY Mellon
$46.19 /

-1.83 (-3.81%)

CFG Citizens Financial
$44.59 /

-0.08 (-0.18%)

STT State Street
$81.09 /

-5.44 (-6.29%)

AZN AstraZeneca
$50.90 /

+0.06 (+0.12%)

JNJ Johnson & Johnson
$161.62 /

+1.12 (+0.70%)

AA Alcoa
$35.37 /

+2.51 (+7.64%)

SPLK Splunk
$135.90 /

-12.5 (-8.42%)

MS Morgan Stanley
$78.53 /

-2.36 (-2.92%)

BK BNY Mellon
$46.19 /

-1.83 (-3.81%)

CFG Citizens Financial
$44.59 /

-0.08 (-0.18%)

STT State Street
$81.09 /

-5.44 (-6.29%)

ALXN Alexion
$163.98 /

+6.55 (+4.16%)

AZN AstraZeneca
$50.90 /

+0.06 (+0.12%)

JNJ Johnson & Johnson
$161.62 /

+1.12 (+0.70%)

LSCC Lattice Semiconductor
$56.81 /

+5.68 (+11.11%)

PPG PPG
$170.26 /

+16.4 (+10.66%)

AA Alcoa
$35.37 /

+2.51 (+7.64%)

EDIT Editas Medicine
$34.50 /

-6.41 (-15.67%)

SPLK Splunk
$135.90 /

-12.5 (-8.42%)

MS Morgan Stanley
$78.53 /

-2.36 (-2.92%)

CFG Citizens Financial
$44.59 /

-0.08 (-0.18%)

ALXN Alexion
$163.98 /

+6.55 (+4.16%)

AZN AstraZeneca
$50.90 /

+0.06 (+0.12%)

JNJ Johnson & Johnson
$161.62 /

+1.12 (+0.70%)

PPG PPG
$170.26 /

+16.4 (+10.66%)

AA Alcoa
$35.37 /

+2.51 (+7.64%)

EDIT Editas Medicine
$34.50 /

-6.41 (-15.67%)

SPLK Splunk
$135.90 /

-12.5 (-8.42%)

Hot Stocks
Sanofi completes acquisition of Kiadis Pharma » 12:01
04/16/21
04/16
12:01
04/16/21
12:01
SNY

Sanofi

$50.93 /

+0.27 (+0.53%)

, KIADF

Kiadis Pharma

$6.55 /

+ (+0.00%)

Sanofi (SNY) and Kiadis…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SNY Sanofi
$50.93 /

+0.27 (+0.53%)

KIADF Kiadis Pharma
$6.55 /

+ (+0.00%)

SNY Sanofi
$50.93 /

+0.27 (+0.53%)

04/06/21 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
02/23/21 BofA
BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
02/10/21 Morgan Stanley
Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley
02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
KIADF Kiadis Pharma
$6.55 /

+ (+0.00%)

11/03/20 Canaccord
Kiadis Pharma downgraded to Hold from Buy at Canaccord
11/02/20 Piper Sandler
Kiadis Pharma downgraded to Neutral from Overweight at Piper Sandler
07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/08/20 Piper Sandler
Kiadis Pharma upgraded to Overweight from Neutral at Piper Sandler
SNY Sanofi
$50.93 /

+0.27 (+0.53%)

SNY Sanofi
$50.93 /

+0.27 (+0.53%)

SNY Sanofi
$50.93 /

+0.27 (+0.53%)

Hot Stocks
FDA approves Bristol-Myers' Opdivo for initial treatment of gastric cancer » 11:56
04/16/21
04/16
11:56
04/16/21
11:56
BMY

Bristol-Myers

$65.52 /

+1.08 (+1.68%)

The U.S. Food and Drug…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BMY Bristol-Myers
$65.52 /

+1.08 (+1.68%)

BMY Bristol-Myers
$65.52 /

+1.08 (+1.68%)

04/13/21 Truist
Bristol-Myers upgraded to Buy at Truist on improving pipeline asset visibility
04/13/21 Truist
Bristol-Myers upgraded to Buy from Hold at Truist
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/08/21 BofA
Gartner added to US 1 List, Bristol-Myers removed at BofA
BMY Bristol-Myers
$65.52 /

+1.08 (+1.68%)

BMY Bristol-Myers
$65.52 /

+1.08 (+1.68%)

BMY Bristol-Myers
$65.52 /

+1.08 (+1.68%)

BMY Bristol-Myers
$65.52 /

+1.08 (+1.68%)

Periodicals
J&J reached out to vaccine rivals to study blood clot risk, WSJ reports » 09:33
04/16/21
04/16
09:33
04/16/21
09:33
JNJ

Johnson & Johnson

$160.44 /

+0.49 (+0.31%)

, PFE

Pfizer

$37.61 /

+0.45 (+1.21%)

, MRNA

Moderna

$159.85 /

-0.25 (-0.16%)

, AZN

AstraZeneca

$50.84 /

+0.97 (+1.95%)

Johnson & Johnson…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PFE Pfizer
$37.61 /

+0.45 (+1.21%)

MRNA Moderna
$159.85 /

-0.25 (-0.16%)

JNJ Johnson & Johnson
$160.44 /

+0.49 (+0.31%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

JNJ Johnson & Johnson
$160.44 /

+0.49 (+0.31%)

04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/13/21 Goldman Sachs
J&J vaccine had numerical blood clot imbalance in trial, says Goldman Sachs
04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 JPMorgan
Vaccine pause 'incremental negative' for J&J, says JPMorgan
PFE Pfizer
$37.61 /

+0.45 (+1.21%)

04/09/21
Pfizer to host conference call
04/06/21 RBC Capital
Pfizer transferred with a Sector Perform at RBC Capital
MRNA Moderna
$159.85 /

-0.25 (-0.16%)

04/15/21 Piper Sandler
Moderna price target raised to $234 from $208 at Piper Sandler
04/13/21 Piper Sandler
Piper reiterates $208 target on Moderna after J&J Covid vaccine pause
04/07/21 Jefferies
Catalent pact with Moderna removes potential overhang, says Jefferies
AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

04/12/21
Fly Intel: Top five analyst downgrades
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/12/21 Argus
AstraZeneca downgraded to Hold from Buy at Argus
PFE Pfizer
$37.61 /

+0.45 (+1.21%)

MRNA Moderna
$159.85 /

-0.25 (-0.16%)

JNJ Johnson & Johnson
$160.44 /

+0.49 (+0.31%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

  • 19
    May
PFE Pfizer
$37.61 /

+0.45 (+1.21%)

MRNA Moderna
$159.85 /

-0.25 (-0.16%)

JNJ Johnson & Johnson
$160.44 /

+0.49 (+0.31%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

PFE Pfizer
$37.61 /

+0.45 (+1.21%)

MRNA Moderna
$159.85 /

-0.25 (-0.16%)

JNJ Johnson & Johnson
$160.44 /

+0.49 (+0.31%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

PFE Pfizer
$37.61 /

+0.45 (+1.21%)

MRNA Moderna
$159.85 /

-0.25 (-0.16%)

JNJ Johnson & Johnson
$160.44 /

+0.49 (+0.31%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

Downgrade
PPD downgraded to Hold from Buy at Deutsche Bank » 09:01
04/16/21
04/16
09:01
04/16/21
09:01
PPD

PPD

$45.80 /

+3.3 (+7.76%)

, TMO

Thermo Fisher

$494.70 /

+16.97 (+3.55%)

Deutsche Bank analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TMO Thermo Fisher
$494.70 /

+16.97 (+3.55%)

PPD PPD
$45.80 /

+3.3 (+7.76%)

PPD PPD
$45.80 /

+3.3 (+7.76%)

08:52 Today William Blair
PPD downgraded to Market Perform from Outperform at William Blair
08:26 Today Evercore ISI
Thermo Fisher price target raised to $540 from $525 at Evercore ISI
08:22 Today Evercore ISI
PPD downgraded to In Line from Outperform at Evercore ISI
TMO Thermo Fisher
$494.70 /

+16.97 (+3.55%)

05:19 Today KeyBanc
PPD downgraded to Sector Weight on takeover at KeyBanc
TMO Thermo Fisher
$494.70 /

+16.97 (+3.55%)

PPD PPD
$45.80 /

+3.3 (+7.76%)

  • 17
    Sep
TMO Thermo Fisher
$494.70 /

+16.97 (+3.55%)

PPD PPD
$45.80 /

+3.3 (+7.76%)

TMO Thermo Fisher
$494.70 /

+16.97 (+3.55%)

PPD PPD
$45.80 /

+3.3 (+7.76%)

Recommendations
Atea selloff on Merck update unwarranted, says William Blair » 08:59
04/16/21
04/16
08:59
04/16/21
08:59
AVIR

Atea Pharmaceuticals

$46.01 /

-8.315 (-15.31%)

, MRK

Merck

$76.67 /

+0.27 (+0.35%)

William Blair analyst Tim…

William Blair analyst Tim Lugo says the weakness yesterday in shares of Atea Pharmaceuticals (AVIR) after Merck (MRK) provided an update on the development program for molnupiravir, an investigational oral antiviral for the treatment of COVID-19, was unwarranted. Based on a planned interim analysis, Merck decided to discontinue development of molnupiravir in hospitalized patients and to amend the inclusion criteria for the Phase III portion of the outpatient study, Lugo tells investors in a research note. Atea closed down by 15% as investors likely saw read-through from the "seemingly negative updates" from molnupiravir to the company's AT-527 development program, says the analyst. Lugo believes the negative reaction was overdone, noting the inclusion criteria for Atea's ongoing Phase II clinical trials of AT-527 for COVID-19 have always used the more stringent inclusion criteria. Further, while both AT-527 and molnupiravir are nucleoside analogs that target RdRp, they do so using slightly different approaches, says the analyst. Lugo keeps an Outperform rating on Atea Pharmaceuticals.

ShowHide Related Items >><<
MRK Merck
$76.67 /

+0.27 (+0.35%)

AVIR Atea Pharmaceuticals
$46.01 /

-8.315 (-15.31%)

AVIR Atea Pharmaceuticals
$46.01 /

-8.315 (-15.31%)

01/29/21 JPMorgan
Atea Pharmaceuticals price target raised to $66 from $45 at JPMorgan
11/24/20 Evercore ISI
Atea Pharmaceuticals initiated with an Outperform at Evercore ISI
11/24/20 Morgan Stanley
Atea Pharmaceuticals initiated with an Overweight at Morgan Stanley
11/24/20 JPMorgan
Atea Pharmaceuticals initiated with an Overweight at JPMorgan
MRK Merck
$76.67 /

+0.27 (+0.35%)

04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/08/21 Alliance Global Partners
Alliance Global Partners sees Fast Track for Immutep efti as meaningful positive
04/08/21 H.C. Wainwright
Alkermes collaboration not as big as investors wanted, says H.C. Wainwright
04/07/21 Mizuho
Mizuho sees Alkermes, Merck collaboration as important next step for nemvaleukin
MRK Merck
$76.67 /

+0.27 (+0.35%)

  • 30
    Oct
MRK Merck
$76.67 /

+0.27 (+0.35%)

MRK Merck
$76.67 /

+0.27 (+0.35%)

AVIR Atea Pharmaceuticals
$46.01 /

-8.315 (-15.31%)

MRK Merck
$76.67 /

+0.27 (+0.35%)

AVIR Atea Pharmaceuticals
$46.01 /

-8.315 (-15.31%)

On The Fly
Fly Intel: Pre-market Movers » 08:58
04/16/21
04/16
08:58
04/16/21
08:58
STT

State Street

$86.53 /

-0.13 (-0.15%)

, ALXN

Alexion

$157.53 /

+2.25 (+1.45%)

, DRNA

Dicerna

$28.54 /

+0.73 (+2.62%)

, EBET

Esports Technologies

$36.05 /

+12.95 (+56.06%)

, CFG

Citizens Financial

$44.66 /

-0.845 (-1.86%)

, ALLY

Ally Financial

$47.65 /

-0.105 (-0.22%)

, PPG

PPG

$153.99 /

+3.17 (+2.10%)

, MS

Morgan Stanley

$80.89 /

+0.11 (+0.14%)

, BK

BNY Mellon

$48.02 /

-0.6 (-1.23%)

, EDIT

Editas Medicine

$41.02 /

-0.5 (-1.20%)

, AZN

AstraZeneca

$50.84 /

+0.97 (+1.95%)

Check out this morning's…

ShowHide Related Items >><<
STT State Street
$86.53 /

-0.13 (-0.15%)

PPG PPG
$153.99 /

+3.17 (+2.10%)

MS Morgan Stanley
$80.89 /

+0.11 (+0.14%)

EDIT Editas Medicine
$41.02 /

-0.5 (-1.20%)

DRNA Dicerna
$28.54 /

+0.73 (+2.62%)

CFG Citizens Financial
$44.66 /

-0.845 (-1.86%)

BK BNY Mellon
$48.02 /

-0.6 (-1.23%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

ALXN Alexion
$157.53 /

+2.25 (+1.45%)

ALLY Ally Financial
$47.65 /

-0.105 (-0.22%)

STT State Street
$86.53 /

-0.13 (-0.15%)

04/09/21 Deutsche Bank
State Street price target raised to $100 from $97 at Deutsche Bank
04/07/21 Barclays
State Street price target raised to $104 from $99 at Barclays
04/01/21 Wells Fargo
State Street price target raised to $90 from $83 at Wells Fargo
04/01/21 Morgan Stanley
State Street price target raised to $103 from $102 at Morgan Stanley
ALXN Alexion
$157.53 /

+2.25 (+1.45%)

03/23/21
Fly Intel: Top five analyst downgrades
03/23/21 SVB Leerink
SVB Leerink moving to sidelines on Alexion, five others on industry concerns
03/23/21 SVB Leerink
Alexion downgraded to Market Perform from Outperform at SVB Leerink
02/04/21 Piper Sandler
Alexion downgraded to Neutral ahead of expected deal closing at Piper Sandler
DRNA Dicerna
$28.54 /

+0.73 (+2.62%)

04:53 Today Goldman Sachs
Dicerna initiated with a Buy at Goldman Sachs
03/18/21
Dicerna to hold a webinar on DCR-AUD disorder
03/02/21 H.C. Wainwright
Dicerna price target raised to $40 from $35 at H.C. Wainwright
EBET Esports Technologies
$36.05 /

+12.95 (+56.06%)

CFG Citizens Financial
$44.66 /

-0.845 (-1.86%)

04/09/21 Jefferies
Citizens Financial price target raised to $47 from $42 at Jefferies
04/07/21 Barclays
Citizens Financial price target raised to $54 from $49 at Barclays
04/01/21 Deutsche Bank
Citizens Financial price target raised to $50 from $44 at Deutsche Bank
03/30/21 Stephens
Citizens Financial price target raised to $54 from $45 at Stephens
ALLY Ally Financial
$47.65 /

-0.105 (-0.22%)

04/15/21 JPMorgan
Ally Financial price target raised to $54 from $48 at JPMorgan
04/13/21 Wells Fargo
Ally Financial price target raised to $57 from $51 at Wells Fargo
04/12/21 BofA
Ally Financial reinstated with a Buy at BofA
04/08/21 Evercore ISI
Ally Financial initiated with an Outperform at Evercore ISI
PPG PPG
$153.99 /

+3.17 (+2.10%)

04/15/21 Citi
Citi opens '30-day negative catalyst watch' on Axalta, PPG
04/07/21 Wells Fargo
PPG price target raised to $173 from $165 at Wells Fargo
03/15/21 Credit Suisse
PPG assumed with a Neutral at Credit Suisse
01/26/21 BofA
PPG upgraded to Buy from Neutral at BofA
MS Morgan Stanley
$80.89 /

+0.11 (+0.14%)

04/09/21 JMP Securities
Goldman Sachs price target raised to $400 from $338 at JMP Securities
04/07/21 Barclays
Morgan Stanley price target raised to $98 from $95 at Barclays
04/01/21 Deutsche Bank
Morgan Stanley price target raised to $79 from $68 at Deutsche Bank
04/01/21 UBS
Morgan Stanley price target raised to $92 from $84 at UBS
BK BNY Mellon
$48.02 /

-0.6 (-1.23%)

04/09/21 Deutsche Bank
BNY Mellon price target raised to $54 from $50 at Deutsche Bank
04/07/21 Barclays
BNY Mellon price target raised to $57 from $55 at Barclays
03/26/21 JPMorgan
JPMorgan sees BNY Mellon, Wells Fargo among banks with most buyback capacity
03/24/21
Fly Intel: Top five analyst upgrades
EDIT Editas Medicine
$41.02 /

-0.5 (-1.20%)

04:56 Today Goldman Sachs
Editas Medicine initiated with a Sell at Goldman Sachs
03/22/21 Credit Suisse
Editas Medicine initiated with an Outperform at Credit Suisse
03/17/21 Guggenheim
Editas Medicine assumed with a Neutral at Guggenheim
03/01/21 Barclays
Editas Medicine downgraded to Equal Weight from Overweight at Barclays
AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/12/21
Fly Intel: Top five analyst downgrades
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/12/21 Argus
AstraZeneca downgraded to Hold from Buy at Argus
STT State Street
$86.53 /

-0.13 (-0.15%)

PPG PPG
$153.99 /

+3.17 (+2.10%)

MS Morgan Stanley
$80.89 /

+0.11 (+0.14%)

EDIT Editas Medicine
$41.02 /

-0.5 (-1.20%)

DRNA Dicerna
$28.54 /

+0.73 (+2.62%)

CFG Citizens Financial
$44.66 /

-0.845 (-1.86%)

BK BNY Mellon
$48.02 /

-0.6 (-1.23%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

ALXN Alexion
$157.53 /

+2.25 (+1.45%)

ALLY Ally Financial
$47.65 /

-0.105 (-0.22%)

  • 15
    Apr
  • 21
    Jan
  • 24
    Jun
STT State Street
$86.53 /

-0.13 (-0.15%)

MS Morgan Stanley
$80.89 /

+0.11 (+0.14%)

CFG Citizens Financial
$44.66 /

-0.845 (-1.86%)

BK BNY Mellon
$48.02 /

-0.6 (-1.23%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

STT State Street
$86.53 /

-0.13 (-0.15%)

PPG PPG
$153.99 /

+3.17 (+2.10%)

MS Morgan Stanley
$80.89 /

+0.11 (+0.14%)

EDIT Editas Medicine
$41.02 /

-0.5 (-1.20%)

DRNA Dicerna
$28.54 /

+0.73 (+2.62%)

BK BNY Mellon
$48.02 /

-0.6 (-1.23%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

ALXN Alexion
$157.53 /

+2.25 (+1.45%)

ALLY Ally Financial
$47.65 /

-0.105 (-0.22%)

PPG PPG
$153.99 /

+3.17 (+2.10%)

MS Morgan Stanley
$80.89 /

+0.11 (+0.14%)

EDIT Editas Medicine
$41.02 /

-0.5 (-1.20%)

CFG Citizens Financial
$44.66 /

-0.845 (-1.86%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

ALXN Alexion
$157.53 /

+2.25 (+1.45%)

ALLY Ally Financial
$47.65 /

-0.105 (-0.22%)

Downgrade
PPD downgraded to Market Perform from Outperform at William Blair » 08:52
04/16/21
04/16
08:52
04/16/21
08:52
PPD

PPD

$45.80 /

+3.3 (+7.76%)

, TMO

Thermo Fisher

$494.70 /

+16.97 (+3.55%)

William Blair analyst…

William Blair analyst John Kreger downgraded PPD (PPD) to Market Perform from Outperform following the acquisition by Thermo Fisher (TMO). The analyst believes the deal is highly likely to close and not likely to attract competitive bidders.

ShowHide Related Items >><<
TMO Thermo Fisher
$494.70 /

+16.97 (+3.55%)

PPD PPD
$45.80 /

+3.3 (+7.76%)

PPD PPD
$45.80 /

+3.3 (+7.76%)

08:26 Today Evercore ISI
Thermo Fisher price target raised to $540 from $525 at Evercore ISI
08:22 Today Evercore ISI
PPD downgraded to In Line from Outperform at Evercore ISI
06:16 Today Truist
PPD downgraded to Hold from Buy at Truist
TMO Thermo Fisher
$494.70 /

+16.97 (+3.55%)

05:19 Today KeyBanc
PPD downgraded to Sector Weight on takeover at KeyBanc
04/15/21 Citi
Thermo Fisher deal for PPD would make sense, says Citi
TMO Thermo Fisher
$494.70 /

+16.97 (+3.55%)

PPD PPD
$45.80 /

+3.3 (+7.76%)

  • 17
    Sep
TMO Thermo Fisher
$494.70 /

+16.97 (+3.55%)

PPD PPD
$45.80 /

+3.3 (+7.76%)

TMO Thermo Fisher
$494.70 /

+16.97 (+3.55%)

PPD PPD
$45.80 /

+3.3 (+7.76%)

Hot Stocks
Horizon Therapeutics announces new Uplizna data at AAN » 08:44
04/16/21
04/16
08:44
04/16/21
08:44
HZNP

Horizon Therapeutics

$93.55 /

+2.17 (+2.37%)

Horizon Therapeutics…

Horizon Therapeutics announced new Uplizna data being presented at the American Academy of Neurology, including new, end-of-study data from the open-label extension period of the pivotal N-MOmentum trial in patients with NMOSD. Uplizna is the first and only FDA-approved anti-CD19 B-cell depleting humanized monoclonal antibody for the treatment of adult patients with anti-aquaporin-4, or AQP4, antibody positive NMOSD. The N-MOmentum Phase 2/3 clinical trial consisted of a 28-week randomized controlled period, or RCP, where study participants received Uplizna or placebo. Following the completion of this period, patients could enter into the OLP for at least two years, during which all patients received Uplizna 300 mg every six months, with follow-up visits at Weeks 2, 4, 13, 26 and 39 of the OLP and every 26 weeks thereafter. Long-term Uplizna treatment provided a sustained reduction in NMOSD attack risk from baseline, regardless of when treatment was initiated: 87.7% of patients who originally received Uplizna in the RCP and 83.4% of patients who originally received placebo in the RCP remained attack-free during the OLP for at least four years. The vast majority of attacks occurred in the first year of treatment. Uplizna treatment was associated with lesion reduction shown by MRI. The mean number of active lesions was similar during the OLP to the number observed in patients who received Uplizna during the RCP. Treatment with Uplizna was generally well-tolerated for at least four years. No new safety signals were identified with prolonged Uplizna treatment and Uplizna-mediated B-cell depletion. Rates of infection or serious infection did not increase with prolonged Uplizna treatment. Levels of immunoglobins declined over time and continued to fall up to five years after the start of the OLP. No clear association between low IgG levels and severe infection can be established. Infusion-related reactions during the N-MOmentum trial were generally mild, with no unexpected safety concerns identified during continued dosing in the OLP. A separate study presented at AAN evaluated patient-reported pain scores for each of five body areas in the previous 24 hours, every four weeks during the RCP of the N-MOmentum trial, as well as during NMOSD attacks. The study used the 11-point Pain Numeric Rating Scale, or NRS-11, where 0 equals no pain and 10 equals the worst pain. Across the five body areas, patients in both groups reported episodic, rather than persistent pain during the RCP. Also in the RCP, fewer patients who received Uplizna than placebo reported a three-point worsening in NRS-11 score relative to baseline. To improve understanding of NMOSD patients' experience throughout the course of their disease, a survey was administered to 151 people living with NMOSD. The survey results demonstrate the importance of finding the right specialist who can identify appropriate screening tests that will lead to an earlier diagnosis and progression toward better patient outcomes. The average time to NMOSD diagnosis was 2.2 years, and over 10 years for some. Only 11% of survey participants were diagnosed with NMOSD when symptoms first appeared. Only 34% first shared their symptoms with an emergency room doctor and 34% first shared their symptoms with a primary care physician. Fear and frustration were the most-commonly reported emotions experienced during initial visits with a medical provider.

ShowHide Related Items >><<
HZNP Horizon Therapeutics
$93.55 /

+2.17 (+2.37%)

HZNP Horizon Therapeutics
$93.55 /

+2.17 (+2.37%)

03/25/21 Guggenheim
Horizon Therapeutics price target raised to $120 from $115 at Guggenheim
03/22/21
Fly Intel: Top five analyst initiations
03/22/21 Morgan Stanley
Horizon Therapeutics resumed with an Overweight at Morgan Stanley
03/18/21 Citi
Horizon Therapeutics price target raised to $120 from $116 at Citi
HZNP Horizon Therapeutics
$93.55 /

+2.17 (+2.37%)

  • 07
    Aug
HZNP Horizon Therapeutics
$93.55 /

+2.17 (+2.37%)

HZNP Horizon Therapeutics
$93.55 /

+2.17 (+2.37%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.